Saturday 17 October 2026
Export APLM’s income statement to Excel — free account
Apollomics Inc.
APLM Healthcare Biotechnology
Apollomics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 million, up 470.9% from fiscal 2024. Insiders bought in the last twelve months.
21.10
0.10
+0.48%
Follow APLM
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Jan '21 | Dec '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 3 | 4 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Altman Z-Score |
(150.05) | (84.01) | (15.74) | (9.58) | 4.00 | — | — | — |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(355.35) | (193.14) | (38.06) | (21.34) | (5.03) | — | 0.86 | — |
Beneish M-Score |
— | — | — | — | (5.07) | — | — | — |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
EV/Operating CF |
0.00 | 0.06 | 0.30 | 0.82 | 0.00 | — | 0.00 | — |
EV/FCF |
0.00 | 0.06 | 0.30 | 0.81 | 0.00 | — | 0.00 | — |
Quick Ratio |
0.88 | 1.32 | 2.79 | 4.19 | 5.20 | 17.51 | 12.79 | — |
Current Ratio |
0.96 | 1.39 | 2.95 | 4.51 | 7.33 | 22.01 | 13.05 | — |
Net Debt/EBITDA |
0.37 | 0.24 | 0.67 | 1.18 | 1.44 | 0.00 | 3.89 | — |
Debt/Assets |
0.00% | 0.00% | 7.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.86 | 0.04 | 0.02 | 0.01 | 0.01 | 0.00 | 0.02 | — |
Operating CF/Net income |
0.95 | 0.53 | 0.25 | 0.18 | 0.46 | 1.72 | 0.48 | — |
Capex/Depreciation |
0.19 | (0.06) | 0.08 | (0.47) | (11.09) | — | (16.66) | — |
Interest Coverage |
(140.65) | (226.13) | (338.86) | (481.57) | (599.63) | (45.27) | (559.44) | — |
| (1,305.45%) | (233.67%) | 84.84% | 72.86% | 55.63% | 0.00% | 0.00% | — | |
| (110.43%) | (157.28%) | (261.79%) | (240.92%) | (64.62%) | 0.00% | (88.05%) | — | |
ROIC |
0.00% | 0.00% | (415.11%) | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
4,021.69% | (1,819.53%) | (650.59%) | (548.32%) | (110.11%) | (24.68%) | (51.27%) | — |
Average Days of Receivables |
98.98 | 0.00 | 0.00 | 0.00 | 19.74 | — | 36.32 | — |
Research and Development Expense of Revenue |
65.07% | 1,649.83% | 2,809.61% | 2,450.38% | 3,374.57% | — | 1,526.26% | — |
Selling, General and Administrative Expense of Revenue |
146.38% | 1,193.28% | 1,696.06% | 687.42% | 1,450.76% | 0.00% | 536.07% | — |
Intangible Assets out of Total Assets |
0.00 | 0.13 | 0.27 | 0.19 | 0.12 | 0.00 | 0.06 | 0.00 |
Share Based Compensation of Revenue |
(11.52%) | 733.78% | 1,042.32% | 247.55% | 770.59% | — | 218.93% | — |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Earnings Yield |
(0.32%) | (0.62%) | (0.07%) | (0.01%) | 0.00% | — | 0.00% | — |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | — |
Revenue per Share |
5.88 | 1.46 | 1.64 | 5.07 | 0.26 | 0.00 | 0.57 | — |
Operating CF per Share |
(7.17) | (28.18) | (58.08) | (150.10) | (10.72) | (0.02) | (9.87) | — |
Capex per Share |
0.03 | (0.02) | 0.07 | (1.29) | (1.87) | 0.00 | (2.81) | — |
Free Cash Flow per Share |
(7.14) | (28.20) | (58.01) | (151.39) | (12.58) | (0.02) | (12.68) | — |
Cash per Share |
2.27 | 9.57 | 50.83 | 181.36 | 17.44 | 0.04 | 42.71 | — |
Shareholders Equity per Share |
(2.20) | 4.77 | 55.42 | (1,570.70) | (52.66) | (0.22) | (35.39) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(2.20) | 4.77 | 55.42 | (1,570.70) | (52.66) | (0.22) | (35.39) | — |
Free Cash Flow |
(10.32) | (28.76) | (43.16) | (43.19) | (50.86) | (0.31) | (45.82) | — |
Working Capital |
(0.27) | 2.87 | 26.37 | 43.43 | 85.81 | 0.72 | 145.58 | — |
Capital Expenditures |
0.05 | (0.02) | 0.05 | (0.37) | (7.55) | — | (10.14) | — |
Net Current Asset Value |
(3.85) | 2.03 | 25.77 | (468.80) | (236.93) | (2.90) | (140.21) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Capex to Sales |
(0.01) | 0.01 | (0.04) | 0.25 | 7.16 | — | 4.92 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
85.00 | 3.92 | 4.16 | 1.60 | 2.43 | — | 1.68 | — |
Cash ROIC |
(11,728.41%) | (196.60%) | (51.82%) | 10.90% | 35.72% | 13.30% | (173.23%) | — |
Accounts Receivable Turnover |
7.20 | 0.00 | 0.00 | 0.00 | 8.05 | — | 0.00 | — |
Average Days of Payables |
— | — | — | — | — | 0.00 | — | — |
Average Receivables |
1.18 | — | — | — | 0.13 | — | — | — |
Average Assets |
9.91 | 34.24 | 65.93 | 99.96 | 146.69 | 137.88 | 84.97 | — |
Average Common Equity |
0.84 | 23.05 | (203.44) | (330.49) | (170.40) | (65.41) | — | — |
Columns are period end dates · fundamentals updated 1 Oct 2026